Table 3 Deterministic mean utility scores used in the model (n=23)
Probabilistic parameters | |||
|---|---|---|---|
Utility item | Mean (s.d.) | α | β |
Disease-free state, no adverse events | 0.989 (0.010) | 106.60 | 1.19 |
Common adverse events (tamoxifen) | 0.970 (0.041) | 15.82 | 0.49 |
Common adverse events (anastrozole) | 0.962 (0.055) | 10.66 | 0.42 |
Vaginal bleeding | 0.933 (0.099) | 5.02 | 0.36 |
Endometrial cancer | 0.913 (0.101) | 6.20 | 0.59 |
Wrist fracture | 0.916 (0.099) | 6.28 | 0.58 |
New contralateral breast cancer | 0.914 (0.097) | 6.72 | 0.63 |
Local/regional recurrence | 0.911 (0.098) | 6.78 | 0.66 |
Deep vein thromboembolism | 0.922 (0.107) | 4.87 | 0.41 |
Pulmonary embolism | 0.890 (0.166) | 2.27 | 0.28 |
Spinal fracture | 0.894 (0.189) | 1.48 | 0.18 |
Hip fracture | 0.858 (0.199) | 1.78 | 0.29 |
Hormonal therapy for distant recurrence | 0.882 (0.105) | 7.44 | 1.00 |
Chemotherapy for distant recurrence | 0.710 (0.254) | 1.56 | 0.64 |
Current health | 0.933 (0.069) | 11.32 | 0.81 |
Hysterectomy | 0.899 (0.101) | 7.10 | 0.80 |
